A 
Atrium Therapeutics, Inc. Common Stock RNA · USD
Health Care · US listing · 🇺🇸 United States
8.38
+0.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$18.6m
FY2018FY2025
Net income
−$76.7m
FY2018FY2025
Free cash flow
−$42.6m
FY2018FY2025
Shareholders' equity
$207.3m
FY2018FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.6m | $10.9m | $9.6m | $9.2m | $9.3m | $6.8m | $2.3m | $379,000 |
| Research and development | $53.8m | $303.6m | $191.0m | $150.4m | $101.2m | $37.6m | $14.5m | $8.4m |
| Operating income | −$76.8m | −$378.9m | −$235.6m | −$178.9m | −$118.1m | −$44.4m | −$17.3m | −$10.5m |
| Net income | −$76.7m | −$322.3m | −$212.2m | −$169.1m | −$117.4m | −$44.0m | −$24.7m | −$11.9m |
| Diluted earnings per share | -4.48 | -2.51 | -2.79 | -2.95 | -4.97 | -1.17 | -1.20 | -0.58 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | $278.4m | $1.56bn | $628.6m | $638.8m | $427.6m | $333.9m | $96.9m | $4.0m |
| Cash and short-term investments | $270.0m | $1.50bn | $595.4m | $610.7m | $405.5m | $328.1m | $94.6m | $3.1m |
| Total liabilities | $71.1m | $138.9m | $127.8m | $60.7m | $46.1m | $27.7m | $162.3m | $45.1m |
| Debt | $3.7m | — | — | — | — | — | $4.5m | $10.3m |
| Shareholders' equity | $207.3m | $1.42bn | $500.8m | $578.1m | $381.4m | $306.2m | −$65.4m | −$41.1m |
| Shares outstanding | 17m | 128m | 76m | 57m | 24m | 37m | 21m | 21m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −$41.1m | −$300.9m | −$119.1m | −$136.3m | −$94.8m | −$37.1m | $2.5m | −$9.7m |
| Capital spending | −$1.4m | −$7.1m | −$4.2m | −$2.8m | −$3.7m | −$1.1m | −$235,000 | −$49,000 |
| Free cash flow | −$42.6m | −$307.9m | −$123.3m | −$139.1m | −$98.6m | −$38.2m | $2.3m | −$9.7m |
| Dividends paid | — | — | — | — | — | −$444,000 | −$106,000 | −$106,000 |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0m | $19.6m | $859,000 | $12.5m | $3.8m | $1.6m | $3.0m | $2.3m |
| Operating income | −$22.6m | −$17.3m | −$48.0m | −$188.8m | −$171.1m | −$131.5m | −$121.0m | −$98.1m |
| Net income | −$20.2m | −$16.6m | −$48.1m | −$174.4m | −$157.3m | −$115.8m | −$102.3m | −$80.4m |
| Diluted earnings per share | -1.18 | -0.97 | -2.81 | -10.19 | -9.19 | -6.76 | -0.80 | -0.63 |
| Cash from operations | −$3.0m | −$31.0m | −$19.0m | −$156.0m | −$199.0m | −$124.0m | −$99.0m | −$65.0m |
| Capital spending | — | −$2.0m | — | −$3.0m | −$3.0m | −$3.0m | −$3.0m | −$1.0m |
| Free cash flow | — | −$33.0m | — | −$159.0m | −$202.0m | −$127.0m | −$102.0m | −$66.0m |
| Total assets | $280.5m | $292.4m | $278.4m | $277.5m | $1.37bn | $1.46bn | $1.56bn | $1.64bn |
| Cash and short-term investments | $264.2m | $267.8m | $270.0m | $270.0m | $1.18bn | $1.38bn | $1.50bn | $1.59bn |
| Debt | $1.7m | $2.7m | $3.7m | $4.0m | $3.9m | $3.9m | $3.8m | $3.8m |
| Shareholders' equity | $214.6m | $234.1m | $207.3m | $212.9m | $1.19bn | $1.33bn | $1.42bn | $1.50bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 26.4% | 22.4% | 5.1% |
| Operating income | -24.6% | 11.6% | — |
| Net income | -23.2% | 11.8% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | -1544.1% | -1801.8% | -1603.2% | — |
| Net margin | -1351.8% | -1615.5% | -1461.9% | — |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.